Vaccination of children with inflammatory rheumatic diseases

Authors

  • Saša Sršen Klinika za dječje bolesti, Klinički bolnički centar Split, Spinčićeva 1, 21000 Split

DOI:

https://doi.org/10.13112/pc.1078

Keywords:

CHILD; ADOLESCENT; VACCINATION; RHEUMATIC DISEASES; PRACTICE GUIDELINE

Abstract

Children with autoimmune inflammatory rheumatic diseases are exposed to an increased risk of infection with infectious diseases due to the disease itself, as well as treatment with immunosuppressive drugs. Vaccination plays a significant role in the prevention of these diseases. Therefore, it is important to have clear and simple guidelines for vaccinating these patients, which we present in this paper. Shortly, it is necessary to follow the national vaccination calendar, with certain restrictions, primarily in the form of avoiding vaccination with live attenuated vaccines. Vaccination should be planned before the start of treatment with immunosuppressive drugs if possible, as well as vaccinating children in quiet stages of the disease, but in no case should necessary treatment be postponed to carry out vaccination. The specialist who is treating a patient with autoimmune rheumatic disease, in coordination with the patient's primary doctor, should have a key role in planning the implementation of the vaccine. In addition to the vaccines provided by the national vaccination program, seasonal influenza vaccination is recommended, while pneumococcal vaccination should be carried out with a 10- or 13-valent vaccine. Of the live attenuated vaccines, in certain circumstances, the use of a booster dose of the measles, mumps, and rubella vaccine, as well as the varicella vaccine, could be considered. Vaccination of adolescents against COVID-19 is considered safe and effective.

 

References

1. Ada G. The importance of vaccination. Front Biosci. 2007;12:1278–90. doi: 10.2741/2146.

2. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93. doi: 10.1002/art.10524.

3. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26(5):663–70. doi: 10.1007/s10067-006-0441-9.

4. Dubé E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. Expert Rev Vaccines. 2015;14(1):99–117. doi: 10.1586/14760584.2015.964212.

5. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35–47. doi: 10.1136/annrheumdis-2022-222574.

6. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–26. doi: 10.1002/acr.22246.

7. Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012;22(6):871–6. doi: 10.1007/s10165-012-0595-z.

8. Toplak N, Avcin T. Safety and efficacy of varicella vaccination in children with JIA treated with biologic therapy. Pediatr Rheumatol. 2014;12.

9. Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24(3):511–6. doi: 10.3109/14397595.2013.843743.

10. Jaeger VK, Hoffman HM, van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry-based study. Rheumatology (Oxford). 2017;56(9):1484–91. doi: 10.1093/rheumatology/kex185.

11. Maritsi DN, Vartzelis G, Kossiva L, Vougiouka O, Garoufi A. The response to the inactivated Hepatitis A vaccine in children with autoinflammatory diseases: a prospective observational controlled study. Rheumatology (Oxford). 2016;55(9):1705–6. doi: 10.1093/rheumatology/kew239.

12. Brunner HI, Tzaribachev N, Cornejo GV, et al.; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatr Rheumatol Online J. 2020;18(1):19. doi: 10.1186/s12969-020-0410-x.

13. Gorelik M, Elizalde A, Wong Williams K, Gonzalez E, Cole JL. Immunogenicity of sequential 13-valent conjugated and 23-valent unconjugated pneumococcal vaccines in a population of children with lupus. Lupus. 2018;27(14):2228–35. doi: 10.1177/0961203318808589.

14. Tacke CE, Smits GP, van der Klis FR, Kuipers IM, Zaaijer HL, Kuijpers TW. Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease. J Allergy Clin Immunol. 2013;131(6):1701–3. doi: 10.1016/j.jaci.2013.01.045.

15. Kobayashi I, Mori M, Yamaguchi K, et al. Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases. Mod Rheumatol. 2015;25(3):335–43. doi: 10.3109/14397595.2014.969916.

16. Clemente Garulo D, Núñez-Cuadros E, Camacho Lovillo M, et al. Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis. Eur J Pediatr. 2023;182(9):4271–84. doi: 10.1007/s00431-023-05080-3.

17. Açarı C, Ünsal E. Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications. Turk J Pediatr. 2017;59(4):357–68. doi: 10.24953/turkjped.2017.04.001.

18. Bizjak M, Heshin-Bekenstein M, Jansen MHA, et al.; PReS Vaccination Working Party. Vaccinology in pediatric rheumatology: past, present and future. Front Pediatr. 2023;10:1098332. doi: 10.3389/fped.2022.1098332.

19. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52. doi: 10.1136/annrheumdis-2019-215882.

20. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023;75(3):449–64. doi: 10.1002/acr.25045.

Published

2025-04-02

How to Cite

Sršen, S. (2025). Vaccination of children with inflammatory rheumatic diseases. Paediatria Croatica, 69(Suppl 2), 245-251. https://doi.org/10.13112/pc.1078

Similar Articles

1-10 of 291

You may also start an advanced similarity search for this article.